Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-25-000223
Filing Date
2025-03-10
Accepted
2025-03-10 19:00:58
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 20223
2 AGREEMENT REGARDING FILING OF JOINT SCHEDULE 13D exh1.htm EX-1 23432
3 POWER OF ATTORNEY REGARDING FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934, A exh2.htm EX-2 27084
  Complete submission text file 0001072613-25-000223.txt   72687
Mailing Address 1954 GREENSPRING DRIVE, SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE, SUITE 600 TIMONIUM MD 21093 410-842-4000
New Enterprise Associates 15, L.P. (Filed by) CIK: 0001629794 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 2 CORPORATE DRIVE, FIRST FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 2 CORPORATE DRIVE, FIRST FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 382-3281
Senti Biosciences, Inc. (Subject) CIK: 0001854270 (see all company filings)

EIN.: 862437900 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92581 | Film No.: 25725364
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)